MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on December 16, 2025. The filing discloses the entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to raise capital through a private placement. The transaction details are as follows:
- Total Gross Proceeds: Approximately $2,253,896 (prior to offering expenses).
- Investor Shares: 1,053,751 shares of Common Stock sold at $1.224 per share for approximately $1,289,792.
- Director Shares: 179,737 shares of Common Stock subscribed by board members at $1.224 per share for approximately $219,998.
- Warrants Issued: Warrants to purchase 1,233,488 shares (1,053,751 Investor Warrants + 179,737 Director Warrants) at an exercise price of $1.36 per share.
- Warrant Terms: Exercisable commencing six months after issuance with a three-year term.
- Use of Proceeds: Funding the starting cost for Step 1 of Part C of the Phase II trial THIO-101 and working capital.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels as this is a transactional filing rather than a periodic financial report.
Material Changes and Unusual Items
The primary material change is the dilution of existing shareholders due to the issuance of 1,233,488 new shares of Common Stock and associated warrants. The transaction includes participation by three directors (Louie Ngar Yee, Stan Smith, and Steven Chaouki) who subscribed for shares and warrants under the Company's 2021 Equity Incentive Plan. The securities are issued as restricted securities under Rule 144 and do not contain registration rights.
Guidance, Outlook, and Risks
Outlook: The Company intends to utilize the net proceeds to advance its clinical development, specifically the THIO-101 Phase II trial. The closing of the private placement is expected on December 18, 2025, subject to customary conditions.
Risks and Contingencies: The securities were sold in reliance on exemptions from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933. The filing notes that the description of the agreement is qualified by the full text of the exhibits attached to the report.
Key Facts for Investor Verification
- Verify the closing date of the private placement (expected December 18, 2025) and the actual net proceeds received after deducting offering expenses.
- Confirm the specific impact of the 1,233,488 new shares and warrants on the Company's fully diluted share count.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Monitor the progress of the THIO-101 Phase II trial to ensure the raised capital is deployed as intended.